| Article Access Statistics|
| Viewed||7276 |
| Printed||350 |
| Emailed||0 |
| PDF Downloaded||320 |
| Comments ||[Add] |
| Cited by others ||9 |
Click on image for details.
| REVIEW ARTICLE
|Year : 2010 | Volume
| Issue : 3 | Page : 129--137
Treatment of cachexia in oncology
EM Tazi, H Errihani
Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco
Background: Cachexia is a complex metabolic syndrome associated with many chronic or end-stage diseases, especially cancer, and is characterized by loss of muscle with or without loss of fat mass. The management of cachexia is a complex challenge that should address the different causes underlying this clinical event with an integrated or multimodal treatment approach targeting the different factors involved in its pathophysiology.
Aims and Objectives : The purpose of this article was to review the current medical treatment of cancer-related cachexia, in particular focusing on combination therapy and ongoing research.
Results : Among the treatments proposed in the literature for cancer-related cachexia, some proved to be ineffective, namely, cyproheptadine, hydrazine, metoclopramide, and pentoxifylline. Among effective treatments, progestagens are currently considered the best available treatment option for cancer-related cachexia, and they are the only drugs approved in Europe. Drugs with a strong rationale that have failed or have not shown univocal results in clinical trials so far include eicosapentaenoic acid, cannabinoids, bortezomib, and anti-TNF-alpha MoAb. Several emerging drugs have shown promising results but are still under clinical investigation (thalidomide, selective cox-2 inhibitors, ghrelin mimetics, insulin, oxandrolone, and olanzapine).
Conclusions : To date, despite several years of coordinated efforts in basic and clinical research, practice guidelines for the prevention and treatment of cancer-related muscle wasting are lacking, mainly because of the multifactorial pathogenesis of the syndrome. From all the data presented, one can speculate that one single therapy may not be completely successful in the treatment of cachexia. From this point of view, treatments involving different combinations are more likely to be successful.
E M Tazi
Department of Medical Oncology, National Institute of Oncology, Rabat
Source of Support: None, Conflict of Interest: None
[FULL TEXT] [PDF]*